The closing price of Transmedics Group Inc (NASDAQ: TMDX) was $74.16 for the day, down -2.34% from the previous closing price of $75.94. In other words, the price has decreased by -$1.78 from its previous closing price. On the day, 851416 shares were traded.
Ratios:
Our analysis of TMDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 3.76 whereas as Long-Term Debt/Eq ratio is at 3.75.
On August 02, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $48.
JP Morgan Downgraded its Overweight to Neutral on October 08, 2020, while the target price for the stock was maintained at $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 08 ’24 when Gordon Stephen sold 1,903 shares for $87.63 per share. The transaction valued at 166,760 led to the insider holds 23,299 shares of the business.
Khayal Tamer I sold 1,417 shares of TMDX for $124,413 on Mar 08 ’24. The Chief Commercial Officer now owns 25,185 shares after completing the transaction at $87.80 per share. On Mar 04 ’24, another insider, Gordon Stephen, who serves as the Chief Financial Officer of the company, sold 15,000 shares for $82.80 each. As a result, the insider received 1,242,000 and left with 25,202 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2.43B and an Enterprise Value of 2.55B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.04 while its Price-to-Book (P/B) ratio in mrq is 17.66. Its current Enterprise Value per Revenue stands at 10.54 whereas that against EBITDA is -330.60.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is 84.28, while the 200-Day Moving Average is calculated to be 72.30.
Shares Statistics:
TMDX traded an average of 578.18K shares per day over the past three months and 603.31k shares per day over the past ten days. A total of 32.67M shares are outstanding, with a floating share count of 31.48M. Insiders hold about 3.79% of the company’s shares, while institutions hold 108.99% stake in the company. Shares short for TMDX as of Feb 29, 2024 were 4.98M with a Short Ratio of 8.62, compared to 5.42M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.23% and a Short% of Float of 17.62%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of $0.11 and a low estimate of -$0.33, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.28 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$0.41 and -$1.24 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.06, with 3 analysts recommending between $1.55 and -$0.9.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $85.5M to a low estimate of $81.2M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $41.55M, an estimated increase of 101.50% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $372.4M, while the lowest revenue estimate was $360M, resulting in an average revenue estimate of $366.8M. In the same quarter a year ago, actual revenue was $241.62M, up 51.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $488.48M in the next fiscal year. The high estimate is $539.8M and the low estimate is $450.14M. The average revenue growth estimate for next year is up 33.20% from the average revenue estimate for this year.
